Kallyope Enters Phase 2 With First-in-class Oral Approach for the Treatment of Both Obesity and Type 2 Diabetes
Kallyope, Inc., a clinical stage biotechnology company discovering and developing novel, oral small-molecule therapeutics for diseases with high unmet need, today announced the initiation of their Phase 2 trial evaluating K-757 and K-833, new oral...
Source: lelezard.com